<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36849">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948921</url>
  </required_header>
  <id_info>
    <org_study_id>DalinTCGH-hsieh-2013-3</org_study_id>
    <nct_id>NCT01948921</nct_id>
  </id_info>
  <brief_title>Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.</brief_title>
  <official_title>Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalin Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalin Tzu Chi General Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our pilot results showed that meperidine reduce patient discomfort during EGD
      (esophagogastroduodenoscopy). But many patients can tolerate EGD well without any sedative
      agents. So we target the use of meperidine on patients expected to have poor tolerance in
      this study, which includ young females with high anxiety level and patients with prior poor
      tolerance. We test the hypothesis that meperidine improves tolerance and alleviates
      discomfort for patients expected to have poor tolerance during diagnostic EGD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>discomfort score during esophageal intubation</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>self-reported discomfort score during esophageal intubation, assessed with a 0 to 10 (0 = none; 10 = unbearable) visual analog scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient discomfort score during the procedure</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients satisfaction score</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient tolerance score evaluated by the endoscopist</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopist satisfaction score</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Patients Undergoing Diagnostic EGD</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml normal saline will be given 5 minutes before EGD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meperidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg intramuscular meperidine will be given 5 minutes before EGD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <arm_group_label>meperidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female youger than 65 years with high anxiety level

          -  patients with previous poor tolerance of EGD

        Exclusion Criteria:

          -  a therapeutic EGD

          -  sedation with other agents

          -  contraindication to Buscopan (hyoscine N-butylbromide) or meperidine

          -  American Society of Anesthesiology (ASA) risk Class 3 or higher, renal failure

          -  age less than 20 years or more than 80 years

          -  pregnancy

          -  refusal to provide written informed consent. All participants signed written informed
             consents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu-Hsi Hsieh, MD</last_name>
    <phone>886-5-2648000</phone>
    <phone_ext>5242</phone_ext>
    <email>hsieh.yuhsi@msa.hinet.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Buddhist Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <zip>622</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Hsi Hsieh, MD</last_name>
      <phone>886052648000</phone>
      <phone_ext>5242</phone_ext>
      <email>hsieh.yuhsi@msa.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Yu-Hsi Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004 Sep;99(9):1692-9.</citation>
    <PMID>15330904</PMID>
  </reference>
  <reference>
    <citation>Hsieh YH, Lin HJ, Hsieh JJ, Tseng KC, Tseng CW, Hung TH, Leung FW. Meperidine as the single sedative agent during esophagogastroduodenoscopy, a double-blind, randomized, controlled study. J Gastroenterol Hepatol. 2013 Jul;28(7):1167-73. doi: 10.1111/jgh.12183.</citation>
    <PMID>23431993</PMID>
  </reference>
  <reference>
    <citation>Ishido S, Kinoshita Y, Kitajima N, Itoh T, Nishiyama K, Tojo M, Yano T, Inatome T, Fukuzaki H, Chiba T. Fentanyl for sedation during upper gastrointestinal endoscopy. Gastrointest Endosc. 1992 Nov-Dec;38(6):689-92.</citation>
    <PMID>1473671</PMID>
  </reference>
  <reference>
    <citation>Laluna L, Allen ML, Dimarino AJ Jr. The comparison of midazolam and topical lidocaine spray versus the combination of midazolam, meperidine, and topical lidocaine spray to sedate patients for upper endoscopy. Gastrointest Endosc. 2001 Mar;53(3):289-93.</citation>
    <PMID>11231385</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dalin Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Yu-Hsi hsieh</investigator_full_name>
    <investigator_title>Chief of Gastroenterology Endoscopy Suite</investigator_title>
  </responsible_party>
  <keyword>EGD</keyword>
  <keyword>tolerance</keyword>
  <keyword>discomfort</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
